Ophthalmology. Retina最新文献

{"title":"Vessels Spanning Avascular Retina in Familial Exudative Vitreoretinopathy.","authors":"D Wade Redick, Joshua M Barnett, G Baker Hubbard","doi":"10.1016/j.oret.2025.02.022","DOIUrl":"https://doi.org/10.1016/j.oret.2025.02.022","url":null,"abstract":"<p><p>The authors describe a fluorescein angiography finding of thick bridging vessels spanning peripheral avascular retina (BVSPAR) in 7.8% of eyes with FEVR. BVSPAR may be associated with poor outcomes and worsening traction after treatment.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macular Atrophy-Related Observations in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial.","authors":"Glenn J Jaffe, Briana Cameron, Giulio Barteselli, Natalia Callaway, Cindy Skalak, John Choong, Shamika Gune","doi":"10.1016/j.oret.2025.02.017","DOIUrl":"https://doi.org/10.1016/j.oret.2025.02.017","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the development of macular atrophy (MA) in eyes treated with the Port Delivery System with ranibizumab (PDS) with those treated with monthly intravitreal ranibizumab injections in the Archway trial.</p><p><strong>Design: </strong>Preplanned exploratory analysis of a phase 3, open-label, randomized trial.</p><p><strong>Participants: </strong>Patients with neovascular age-related macular degeneration (nAMD) diagnosed within 9 months of screening, previously treated with and responsive to anti-vascular endothelial growth factor therapy.</p><p><strong>Methods: </strong>Eyes were randomized 3:2 to treatment with the PDS 100 mg/mL with fixed 24-week (Q24W) refill-exchanges (PDS Q24W) or intravitreal ranibizumab 0.5 mg injections every 4 weeks (monthly ranibizumab).</p><p><strong>Main outcome measures: </strong>Prevalence, incidence, and progression of MA.</p><p><strong>Results: </strong>The analysis population consisted of 415 eyes (248 and 167 eyes in the PDS Q24W and monthly ranibizumab arms, respectively). At study baseline, MA was observed in 22.3% (PDS Q24W) and 20.4% (monthly ranibizumab) of eyes. At week 96, prevalence of MA was 39.1% and 39.2% while incidence of new MA in eyes without MA at baseline was 20.0% and 22.6% in the PDS Q24W and monthly ranibizumab arms, respectively. In eyes without baseline MA, mean MA area at week 96 was 0.4 in the PDS Q24W arm and 3.8 mm² in the monthly ranibizumab arm with a difference of 3.4mm², (P = 0.054) favoring PDS. In eyes with baseline MA, mean change in MA area from baseline to week 96 was +2.2 mm² for both the PDS Q24W and monthly ranibizumab arms.</p><p><strong>Conclusions: </strong>In the Archway trial, which compared PDS Q24W with monthly ranibizumab injections for nAMD treatment over 2 years, prevalence and incidence of MA were similar between arms over the study duration. In eyes without baseline MA, PDS-treated eyes had less MA area by 3.4 mm², a potentially clinically meaningful (although not statistically significant) difference. The results of this prespecified exploratory analysis suggest that PDS treatment is not associated with higher incidence or progression of MA when compared with monthly injections of ranibizumab. In eyes without baseline MA, the progression of atrophy area was 4 times less in PDS-treated eyes. Additional studies could further elucidate this observation.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorescein Angiography May Predict Surgical Outcomes of Tractional Retinal Detachment in Familial Exudative Vitreoretinopathy.","authors":"Tomoyuki Oga, Fukutaro Mano, Kazuki Kuniyoshi, Chiharu Iwahashi, Hiroyuki Kondo, Shunji Kusaka","doi":"10.1016/j.oret.2025.02.018","DOIUrl":"10.1016/j.oret.2025.02.018","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate factors associated with the surgical outcomes of tractional retinal detachment (TRD) in eyes with familial exudative vitreoretinopathy (FEVR).</p><p><strong>Design: </strong>Retrospective chart review.</p><p><strong>Subjects: </strong>Patients who underwent surgeries for TRD associated with FEVR between April 2011 and April 2022 and had a follow-up of ≥18 months were included in the analysis.</p><p><strong>Methods: </strong>Vitrectomy was performed on 47 eyes, with scleral buckling in 4 eyes and simultaneous lensectomy in 26 eyes.</p><p><strong>Main outcome measures: </strong>Data, including sex, age at the first surgery, disease stage, extent of fibrovascular proliferation (FVP, within 3 hours or >3 hours), preoperative fluorescein angiography (FA) grading (grade 1: mild leakage caused by FVP, grade 2: severe leakage), surgical outcomes, and complications, were collected.</p><p><strong>Results: </strong>The age at the initial surgery ranged from 1 month to 15 years (median: 6 months). Thirty-two eyes were from male patients, and 15 eyes were from female ones. Only 1 eye in 25 patients was affected. In 11 patients, bilateral eyes were involved. In total, 8 eyes presented with stage 3 FEVR, 31 with stage 4, and 8 with stage 5. The preoperative FA was performed on 38 of 47 eyes. There were 26 eyes with FA grade 1 and 12 eyes with FA grade 2. The retina was reattached in 33 (70.2%) eyes at the final examination. Based on the univariate logistic regression analysis, a higher retinal reattachment (RA) rate was significantly associated with a lower FEVR stage (P = 0.0001), FA grade (P = 0.0008), and preoperative extent of FVP (P = 0.02). In the multivariate logistic regression analysis, only FA grade was significantly associated with RA (P = 0.04, odds ratio: 9.0, 95% confidence interval: 1.2-7.0 × 10).</p><p><strong>Conclusion: </strong>Eyes with TRD associated with FEVR in patients with mild FA leakage had a higher RA rate. Hence, the use of FA in evaluating disease activity can be useful in predicting surgical outcomes.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Imaging Analysis of Supra-retinal Pigment Epithelium Granular Deposits in Treatment-Naive Full-Thickness Macular Holes.","authors":"Daniela Bacherini, Stefano Mercuri, Andrea Govetto, Laura Di Leo, Tomaso Caporossi, Francesco Faraldi, Stanislao Rizzo, Gianni Virgili, Fabrizio Giansanti","doi":"10.1016/j.oret.2025.02.016","DOIUrl":"10.1016/j.oret.2025.02.016","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the morphology and provide anatomical correlations of supra-retinal pigment epithelium (RPE) granular deposits in full-thickness macular holes (FTMHs).</p><p><strong>Design: </strong>Retrospective, observational, single-center study.</p><p><strong>Participants: </strong>Patients with idiopathic FTMH presenting to the University of Florence Eye clinic.</p><p><strong>Methods: </strong>Thirty-six eyes of 34 patients with a diagnosis of treatment-naive FTMH, scheduled for surgery, underwent multimodal imaging including spectral-domain OCT (SD-OCT), en-face OCT, and adaptive optics ophthalmoscopy (AOO). Different methodologies were evaluated to determine the location and topographical correspondence of granulations. The total volume of supra-RPE granular deposits was correlated to the macular hole (MH) characteristics and SD-OCT markers of photoreceptor damage with Spearman correlation coefficient (CC).</p><p><strong>Main outcome measures: </strong>Morphological correlations in FTMHs using SD-OCT and AOO.</p><p><strong>Results: </strong>Using AOO, supra-RPE granular deposits appeared as hyper-reflective structures, mostly found within the minimum linear diameter (MLD) (104 of 139 deposits, 74%). Different imaging techniques were equally effective in the topographical identification of supra-RPE granular deposits (P > 0.30). The total volume of supra-RPE granular deposits significantly increased with stages B and C of FTMH, inversely correlated to the corrected ellipsoid zone (EZ) reflectivity (CC = -0.62) and positively correlated to the length of the EZ defect (CC = +0.41) and MH diameter at the base (CC = +0.35) and MLD (CC = +0.42) (all P < 0.05).</p><p><strong>Conclusions: </strong>Supra-RPE granular deposits can be identified accurately using AOO and en-face OCT. Characteristics using AOO and anatomical correlations at SD-OCT indicate supra-RPE granular deposits as signs of photoreceptor degeneration.</p><p><strong>Financial disclosure(s): </strong>The authors have no proprietary or commercial interest in any materials discussed in this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Progression of Myopic Maculopathy in a Long-Term Follow-Up of a European Cohort: Imaging Features and Visual Outcomes.","authors":"Matteo Mario Carlà, Francesco Boselli, Federico Giannuzzi, Emanuele Crincoli, Fiammetta Catania, Tomaso Caporossi, Stanislao Rizzo, Carlos Mateo","doi":"10.1016/j.oret.2025.02.015","DOIUrl":"10.1016/j.oret.2025.02.015","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the longitudinal progression of myopic maculopathy in a European cohort of highly myopic patients, analyzing the disease natural history and its impact on visual function.</p><p><strong>Design: </strong>Retrospective, observational monocentric cohort study.</p><p><strong>Participants: </strong>The study included 1228 eyes from 781 highly myopic patients with a minimum follow-up time of 5 years. We collected best-corrected visual acuity (BCVA) measurement, axial length (AXL), fundus photography, and spectral-domain OCT, along with data regarding intraocular pressure-lowering drugs and glaucoma surgery.</p><p><strong>Methods: </strong>Myopic atrophic maculopathy (MAM) was graded according to the ATN classification system. The presence of myopic staphyloma followed Curtin's classification. The development of myopic neovascular maculopathy (MNM) and myopic tractional maculopathy (MTM) was also assessed, along with the presence of dome-shaped macula (DSM) and lacquer cracks (LCs) at baseline.</p><p><strong>Main outcome measures: </strong>The rate of MAM progression and visual outcomes. The secondary outcome included the correlation with the presence of staphyloma subtypes and the development of MNM and MTM.</p><p><strong>Results: </strong>The mean AXL was 31.6 ± 2.8 mm. Myopic atrophic maculopathy progressed in 57% of eyes over a mean follow-up of 11.4 years. Eyes with patchy atrophy progressed in 81% of cases, and 47% of them developed macular atrophy, whereas eyes with tessellated fundus progressed in only 19% of cases. The presence of a macular-involving staphyloma was associated with progression, particularly for type IX (86% rate of progression). A significant decline in BCVA (≥2 lines) was observed in 35.8% of eyes and correlated with AXL, glaucoma surgery, patchy atrophy, MNM, and MTM development (all P < 0.05). Active MNM developed in 190 eyes (15%), significantly associated with baseline LCs (odds ratio [OR], 2.56) and DSM (OR, 4.95), determined faster progression toward macular atrophy (OR, 5.91). Myopic tractional maculopathy complications were observed in 314 eyes (26%) and significantly correlated with the presence of a type I and II staphyloma.</p><p><strong>Conclusions: </strong>More than half of eyes with myopic maculopathy tended to progress, in particular in cases with patchy atrophy at baseline and in eyes developing MNM or MTM, which caused worse vision loss during the study period. Although DSM and LCs correlated with neovascular complications, the shape of the posterior staphyloma correlated with tractional complications.</p><p><strong>Financial disclosure(s): </strong>The authors have no proprietary or commercial interest in any materials discussed in this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Remodeling of Abnormal Choroidal Vasculature.","authors":"Eliza Anthony, Jefila Jayakumar, Prabu Baskaran","doi":"10.1016/j.oret.2025.01.003","DOIUrl":"https://doi.org/10.1016/j.oret.2025.01.003","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Cindy X Cai, Akihiko Nishimura, George Hripcsak","doi":"10.1016/j.oret.2025.01.014","DOIUrl":"https://doi.org/10.1016/j.oret.2025.01.014","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733-743.).","authors":"Flora Lum","doi":"10.1016/j.oret.2025.01.013","DOIUrl":"https://doi.org/10.1016/j.oret.2025.01.013","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-arterial chemotherapy for retinoblastoma, outcomes analysis in 357 eyes: 13 years of experience in a referral center in Brazil.","authors":"Luiz F Teixeira, Carla R P D Macedo, José R F Fonseca, Bruna Morales, Monique K Mangeon, Bruno A Miranda, Ricardo Casaroli-Marano, Juliana M F Sallum","doi":"10.1016/j.oret.2025.02.013","DOIUrl":"https://doi.org/10.1016/j.oret.2025.02.013","url":null,"abstract":"<p><strong>Objective: </strong>Evaluate the outcomes of intra-arterial chemotherapy (IAC) for the treatment of naive and non-naive retinoblastoma eyes. Ocular survival rates, risk factors for enucleation, ocular complications, metastatic disease, and overall survival were analyzed.</p><p><strong>Design: </strong>A retrospective, single-institution study PARTICIPANTS: A total of 300 patients treated with IAC between April 2010 and April 2023 were included.</p><p><strong>Interventions: </strong>During IAC infusions, 1-3 drugs were used (melphalan, 3.0-7.5mg; topotecan, 0.3-2.0 mg; carboplatin, 20-50 mg). Adjuvant therapy was used as needed to consolidate treatment.</p><p><strong>Main outcome measures: </strong>Ocular survival rates, ocular complications, and the risk factors for enucleation were measured.</p><p><strong>Results: </strong>A total of 357 eyes were treated with 1,536 IAC infusions, with a median of four cycles per eye, and followed for 60.69 months. The Kaplan-Meier estimates for the overall ocular survival were 90% at 1, 89% at 2, and 86% at 5 years. No difference in ocular survival was found between IAC indications (primary 88% vs secondary 85% vs bridge 89%; p = 0.52) or for the use of tandem therapy (tandem 85% vs no tandem 87%; p = 0.93). Intravitreal chemotherapy as adjuvant therapy was used in 31.37% and plaque therapy in 5% of the eyes. The group did not receive external beam radiation. Univariable and multivariable analyses showed that the presence of subretinal seeds was significantly associated with an increased risk of enucleation, and the use of ophthalmic artery (OA) ostium in >50% of infusions per eye was a protective factor to avoid enucleation. Retinal and/or choroidal vascular, ischemic, or atrophic effects were the most frequent complications found in 5.0% of the eyes. Metastatic disease was observed in 0.33% of the patients. The overall 5-year patient survival was 99.3%.</p><p><strong>Conclusions: </strong>The use of IAC in different indications (primary, secondary, bridge, and tandem) to treat naive or recurrent-refractory retinoblastomas showed successful results. Most eyes were preserved. Subretinal seeds at presentation were associated with a high enucleation risk. The use of the OA ostium for drug delivery avoided enucleation.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal Silicone Oil Bubbles after Perforating Needlestick Open-Globe Injury.","authors":"Taariq K Mohammed, Jonathan F Russell","doi":"10.1016/j.oret.2025.01.009","DOIUrl":"https://doi.org/10.1016/j.oret.2025.01.009","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}